Show simple item record

dc.contributor.authorRobert, C
dc.contributor.authorSchachter, J
dc.contributor.authorLong, G
dc.contributor.authorArance, A
dc.contributor.authorGrob, J
dc.contributor.authorMortier, L
dc.contributor.authorDaud, A
dc.contributor.authorCarlino, M
dc.contributor.authorMcNeil, C
dc.contributor.authorLotem, M
dc.contributor.authorLarkin, J
dc.contributor.authorLorigan, Paul C
dc.contributor.authorNeyns, B
dc.contributor.authorBlank, C
dc.contributor.authorHamid, O
dc.contributor.authorMateus, C
dc.contributor.authorShapira-Frommer, R
dc.contributor.authorKosh, M
dc.contributor.authorZhou, H
dc.contributor.authorIbrahim, N
dc.contributor.authorEbbinghaus, S
dc.contributor.authorRibas, A
dc.date.accessioned2015-08-10T12:28:41Zen
dc.date.available2015-08-10T12:28:41Zen
dc.date.issued2015-06-25en
dc.identifier.citationPembrolizumab versus Ipilimumab in Advanced Melanoma. 2015, 372 (26):2521-32 N. Engl J Meden
dc.identifier.issn1533-4406en
dc.identifier.pmid25891173en
dc.identifier.doi10.1056/NEJMoa1503093en
dc.identifier.urihttp://hdl.handle.net/10541/565800en
dc.description.abstractThe immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshAntibodies, Monoclonalen
dc.subject.meshAntibodies, Monoclonal, Humanizeden
dc.subject.meshAntineoplastic Agentsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMelanomaen
dc.subject.meshMiddle Ageden
dc.subject.meshProgrammed Cell Death 1 Receptoren
dc.subject.meshSkin Neoplasmsen
dc.subject.meshSurvival Analysisen
dc.subject.meshYoung Adulten
dc.titlePembrolizumab versus Ipilimumab in Advanced Melanoma.en
dc.typeArticleen
dc.contributor.departmentUniv Paris Sud, F-94805 Villejuif, France.en
dc.identifier.journalThe New England Journal of Medicineen
html.description.abstractThe immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.


This item appears in the following Collection(s)

Show simple item record